Two controlled trials conducted by myself and colleagues in Dundee (Worral *et al*, 1979) are representative and discussed the issues at that time. One of those trials, in which tryptophan was compared with lithium and tryptophan in combination, is regularly quoted in the subsequent combined studies and used as evidence for lithium having an augmenting effect on other antidepressants. We specifically stated that the design of that trial could not possibly prove that. The simplest explanation in that trial was that lithium was acting alone and, in truth, tryptophan was only used because we did not obtain ethical permission for a placebo comparison.

What seems to have happened is that influential figures twenty years ago stated that lithium did not have important acute antidepressant effects and, with minor modifications, that statement has been authoritatively repeated in nearly all reviews since. What the combined studies have shown is that when a first-line treatment has proved ineffective and the clinician has then tried lithium, he has not believed his own eyes when he has seen a major acute antidepressant response, and some form of potentiation or augmentation of the first drug by lithium is instead suggested.

Why expose patients simultaneously to two drugs without first trying each separately, especially if, as is likely, continuation treatment is going to be needed? It may be that in a few patients lithium does need to be used along with another antidepressant, or a neuroleptic, and it would be surprising if on occasion two antidepressants from a different class did not have more effect than one. A controlled trial to prove that would be feasible, but before going to that trouble an open-minded reappraisal of the effects of lithium alone might make such a trial less necessary.

ERNEST P. WORRALL

Southern General Hospital,
Glasgow G51 HTF

References

STOKES, P. E., STOLL, P. M., SHAMOIAN, C. A. & PATTON, M. J. (1971) Efficacy of lithium as acute treatment of manic-depressive illness. *Lancet*, *i*, 1319–1325.

WORRAL, E. P., MOODY, J. P., PEET, M., DICK, P., SMITH, A. CHAMBERS, C. A., ADAMS, M. & NAYLOR, G. J. (1979) Controlled studies of the acute antidepressant effects of lithium. *British Journal of Psychiatry*, **135**, 255–262.

At Risk Drinking

Sir:I was delighted to read the article by Dr King (*Journal*, May 1986, **148**, 533–540). In this and other articles Dr King has used the CAGE Questionnaire. Unfortunately, he has repeated a failure of other authors to attribute the questionnaire to the correct source. The CAGE questions were developed by me and my colleagues at the University of North Carolina in the late 1960s. The CAGE questions have been used in many different studies by now, and recently (Ewing, 1984) I published a paper in the *Journal of the American Medical Association* describing their origins, clinical use and efficacy. That reference might be the best one for Dr King and others to use in future.

JOHN A. EWING

University of North Carolina
2557 Ravenhill Drive, Building 1A
Fayetteville, North Carolina 28303

References

EWING, J. A. (1984) Detecting alcoholism: The CAGE Questionnaire. *Journal of the American Medical Association*, **252**, 1905–1907.

Anhedonic Depression

Sir: Young *et al* (*Journal*, March 1986, **148**, 257–267) have suggested the possible existence of two subtypes of endogenous depression—anhedonic subtype and vegetative sub-type. Earlier, Hibbert *et al* (1984) reported that symptoms of reduced interest and pleasure and of low mood represent features of the state of depression which are related to each other, but are not much related to the more 'biological' symptoms of reduced sleep and appetite.

In a study of 34 RDC major depressives, I classified the patients as anhedonic and non-anhedonic based on high or low scores on the sub-scale anhedonia-asociality of the Scale for the Assessment of Negative symptoms (SANS) (Andreasen, 1981). The anhedonic sub-type had a significantly ($P < 0.001$) longer duration of illness than the non-anhedonic sub-type. Almost 20% of anhedonic depressives had a duration of illness longer than nine months with treatment. The response to tricyclic antidepressants was unsatisfactory in the anhedonic depressives and the need for adjuvant therapy with electroconvulsive shocks and antipsychotics was significantly ($P < 0.01$) more often required for them. Anhedonic depressives also required a much longer duration of treatment than the non-anhedonic depressives (Chaturvedi & Sarmukaddam, 1986). Interestingly, anhedonic depressives had significantly higher total scores on SANS than non-anhedonic depressives.

These findings help further in identifying an anhedonic sub-type of depression. However, in my study, no demographic differences were observed